Marcelino JM
Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy
- Autores: Barroso H, Borrego P, Marcelino JM, Novo C, Quintas A, Rocha C, Taveira N
- Ano de Publicação: 2010
- Journal: Journal of Virology
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Potent+and+broadly+reactive+HIV-2+neutralizing+antibodies+elicited+by+a+vaccinia+vector-prime
Human immunodeficiency virus type 2 (HIV-2) infection affects about 1 to 2 million individuals, the majority living in West Africa, Europe, and India. As for HIV-1, new strategies for the prevention of HIV-2 infection are needed. Our aim was to produce new vaccine immunogens that elicit the production of broadly reactive HIV-2 neutralizing antibodies (NAbs). […]
Ler mais
Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response
- Autores: Barroso H, Bártolo I, Borrego P, Calado R, Cavaco-Silva P, Família C, Gomes P, Leitner T, Marcelino JM, Quintas A, Rocha C, Rosado L, Skar H, Taveira N
- Ano de Publicação: 2013
- Journal: Retrovirology
- Link: http://www.retrovirology.com/content/10/1/110
Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4+ T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and resulting HIV-2 escape during acute infection and their impact in HIV-2 evolution and disease progression remain largely unknown. Our objective was to characterize the Nab response and the molecular and phenotypic evolution of HIV-2 in association with Nab escape in the first years of infection in two children infected at birth.
Ler mais
- Autores: Barroso H, Bártolo I, Borrego P, Família C, Marcelino JM, Quintas A, Taveira N
- Ano de Publicação: 2011
- Journal: PLoS One
- Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=23&SID=P2WA5hwy5j35Sqjoq2z&page=1&doc=1
Background: Unlike in HIV-1 infection, the majority of HIV-2 patients produce broadly reactive neutralizing antibodies, control viral replication and survive as elite controllers.
Ler mais
An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity
- Autores: Barroso H, Borrego P, Calado R, Marcelino JM, Pereira P, Quintas A, Taveira N
- Ano de Publicação: 2013
- Journal: Aids
- Link: http://www.ncbi.nlm.nih.gov/pubmed/23324659
To produce new fusion inhibitor peptides for HIV-1 and HIV-2 based on ancestral envelope sequences.
Ler mais
Baseline susceptibility of primary HIV-2 to entry inhibitors.
- Autores: Antunes F, Barroso H, Bártolo I, Borrego P, Caixas U, Calado R, Cavaco-Silva P, Doroana M, Maltez F, Marcelino JM, Rocha C, Taveira N
- Ano de Publicação: 2012
- Journal: Antiviral Therapy
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Baseline+susceptibility+of+primary+HIV-2+to+entry+inhibitors
BACKGROUND:
The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown.
Ler mais
Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia.
- Autores: Baptista AP, Cavaleiro R, Fernandes S, Foxall RB, Gomes P, Marcelino JM, Soares RS, Sousa AE., Taveira N, Tendeiro R, Victorino RM
- Ano de Publicação: 2012
- Journal: Aids
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Memory+B-cell+depletion+is+a+feature+of+HIV-2+infection+even+in+the+absence+of+detectable+viremia
OBJECTIVE:
Memory B-cell loss has long been recognized as an important contributor to HIV immunodeficiency. HIV-2 infection, which is characterized by a slow rate of progression to AIDS and reduced to undetectable viremia, provides a unique model to investigate B-cell disturbances.
Ler mais
Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.
- Autores: Antunes F, Barroso H, Borrego P, Doroana M, Família C, Maltez F, Marcelino JM, Nilsson C, Quintas A, Taveira N
- Ano de Publicação: 2012
- Journal: Aids
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Resistance+to+antibody+neutralization+in+HIV-2+infection+occurs+in+late+stage+disease+and+is+associated+with+X4+tropism
OBJECTIVES:
To characterize the nature and dynamics of the neutralizing antibody (NAb) response and escape in chronically HIV-2 infected patients.
Ler mais
